Form 8-K - Current report:
SEC Accession No. 0001104659-25-056697
Filing Date
2025-06-05
Accepted
2025-06-05 09:26:04
Documents
15
Period of Report
2025-06-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2517243d1_8k.htm   iXBRL 8-K 29880
2 EXHIBIT 10.1 tm2517243d1_ex10-1.htm EX-10.1 29499
3 EXHIBIT 99.1 tm2517243d1_ex99-1.htm EX-99.1 9586
7 GRAPHIC image_001.jpg GRAPHIC 4340
  Complete submission text file 0001104659-25-056697.txt   252532

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA clrb-20250605.xsd EX-101.SCH 3017
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE clrb-20250605_lab.xml EX-101.LAB 34239
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clrb-20250605_pre.xml EX-101.PRE 22360
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2517243d1_8k_htm.xml XML 3568
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36598 | Film No.: 251025865
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)